GLP‑1 Weight‑Loss Drugs Reshape U.S. Healthcare, Consumer Spending and Pharma Market

GLP‑1 receptor agonists such as Wegovy, Ozempic, Zepbound and Mounjaro have moved from diabetes treatment to a mainstream weight‑loss solution. Gallup data show that about 11 % of U.S. adults were using a GLP‑1 for weight loss in 2026, up from 3 % in 2024, and prescriptions are now common in primary‑care offices and tele‑health clinics. The surge has driven a shift in household food purchasing: a Cornell University study found a 5.3 % drop in overall grocery spend, with larger cuts (up to 8 %) on ultra‑processed and fast‑food items, while spending on fruits, yogurt and protein snacks rose. This change is reshaping supermarket sales, fast‑food revenue and even airline fuel consumption, as lighter passenger loads generate estimated fuel savings of up to $580 million a year. The market for GLP‑1 medicines is projected to reach $105 billion globally by 2030, with Brazil’s pharmacy chain Pague Menos reporting a 157 % Q1 sales increase and GLP‑1 products accounting for 9.1 % of its revenue. Side‑effect reports and personal experiences reveal issues such as gastrointestinal upset, hair loss, and rare liver problems, while many users conceal treatment from partners. Pediatric guidelines now allow use in adolescents 12 years and older, and wellness retreats in South Carolina offer GLP‑1 support programs. Dermatologists note that rapid weight loss can produce “Ozempic face,” prompting a market for specialized skincare, though it cannot replace lost facial volume.